Increase in Medicare Claims & Fraud Measures Intensified

The U.S. government has identified a significant increase in Medicare claims linked to tissue and organ transplants, necessitating robust anti-fraud measures. Officials have reported that the value of Medicare claims for allografts has surged from $200 million in 2019 to an estimated $14.4 billion by 2025. This sharp rise underscores the urgency of addressing potential fraud within the healthcare system.

In response, the White House Anti-Fraud Task Force, spearheaded by Vice President JD Vance, alongside the Centers for Medicare and Medicaid Services (CMS), has intensified scrutiny of these claims. Since March, a majority of allograft claims under review have been denied, with 4,200 claims found potentially fraudulent, resulting in dubious payouts amounting to $224 million by May. Efforts to clamp down on fraud have extended to the Durable Medical Equipment (DME) sector, leading to payment suspensions for over 100 suppliers and revocation of billing privileges for 725 more, impacting those responsible for over 8% of Medicare-funded DME in 2025.

CMS Administrator Mehmet Oz highlighted the extensive financial ramifications during a press briefing, emphasizing the broader implications on healthcare providers and systems. A spokesperson from Vice President Vance's office expressed confidence in ongoing enforcement strategies, noting significant advancements in curtailing fraud via rigorous measures and moratoria on new DME companies. The administration claims to have disrupted illicit activities valued at nearly $220 million, demonstrating its commitment to safeguarding patients and holding fraudulent entities accountable within the healthcare market.